A M Fager1,2, K R Machlus3, M Ezban4, M Hoffman2,5. 1. Division of Hematology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. 2. Pathology and Laboratory Medicine Service, Durham Veterans Affairs Medical Center, Durham, NC, USA. 3. Division of Hematology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 4. Pharmacology, Novo Nordisk A/S, Måløv, Denmark. 5. Department of Pathology, Duke University School of Medicine, Durham, NC, USA.
Abstract
Essentials Factor VIIa binds activated platelets to promote hemostasis in hemophilia patients with inhibitors. The interactions and sites responsible for platelet-FVIIa binding are not fully understood. Endothelial cell protein C receptor (EPCR) is expressed on activated human platelets. EPCR binding enhances the efficacy of a FVIIa variant and could impact design of new therapeutics. SUMMARY: Background High-dose factor VIIa (FVIIa) is routinely used as an effective bypassing agent to treat hemophilia patients with inhibitory antibodies that compromise factor replacement. However, the mechanism by which FVIIa binds activated platelets to promote hemostasis is not fully understood. FVIIa-DVQ is an analog of FVIIa with enhanced tissue factor (TF)-independent activity and hemostatic efficacy relative to FVIIa. Our previous studies have shown that FVIIa-DVQ exhibits greater platelet binding, thereby suggesting that features in addition to lipid composition contribute to platelet-FVIIa interactions. Objectives Endothelial cell protein C receptor (EPCR) also functions as a receptor for FVIIa on endothelial cells. We therefore hypothesized that an interaction with EPCR might play a role in platelet-FVIIa binding. Methods/results In the present study, we used flow cytometric analyses to show that platelet binding of both FVIIa and FVIIa-DVQ is partially inhibited in the presence of excess protein C or an anti-EPCR antibody. This decreased binding results in a corresponding decrease in the activity of both molecules in FXa and thrombin generation assays. Enhanced binding to EPCR was sufficient to account for the increased platelet binding of FVIIa-DVQ compared with wild-type FVIIa. As EPCR protein expression has not previously been shown in platelets, we confirmed the presence of EPCR in platelets using immunofluorescence, flow cytometry, immunoprecipitation, and mass spectrometry. Conclusions This work represents the first demonstration that human platelets express EPCR and suggests that modulation of EPCR binding could be utilized to enhance the hemostatic efficacy of rationally designed FVIIa analogs.
Essentials Factor VIIa binds activated platelets to promote hemostasis in hemophiliapatients with inhibitors. The interactions and sites responsible for platelet-FVIIa binding are not fully understood. Endothelial cell protein C receptor (EPCR) is expressed on activated human platelets. EPCR binding enhances the efficacy of a FVIIa variant and could impact design of new therapeutics. SUMMARY: Background High-dose factor VIIa (FVIIa) is routinely used as an effective bypassing agent to treat hemophiliapatients with inhibitory antibodies that compromise factor replacement. However, the mechanism by which FVIIa binds activated platelets to promote hemostasis is not fully understood. FVIIa-DVQ is an analog of FVIIa with enhanced tissue factor (TF)-independent activity and hemostatic efficacy relative to FVIIa. Our previous studies have shown that FVIIa-DVQ exhibits greater platelet binding, thereby suggesting that features in addition to lipid composition contribute to platelet-FVIIa interactions. Objectives Endothelial cell protein C receptor (EPCR) also functions as a receptor for FVIIa on endothelial cells. We therefore hypothesized that an interaction with EPCR might play a role in platelet-FVIIa binding. Methods/results In the present study, we used flow cytometric analyses to show that platelet binding of both FVIIa and FVIIa-DVQ is partially inhibited in the presence of excess protein C or an anti-EPCR antibody. This decreased binding results in a corresponding decrease in the activity of both molecules in FXa and thrombin generation assays. Enhanced binding to EPCR was sufficient to account for the increased platelet binding of FVIIa-DVQ compared with wild-type FVIIa. As EPCR protein expression has not previously been shown in platelets, we confirmed the presence of EPCR in platelets using immunofluorescence, flow cytometry, immunoprecipitation, and mass spectrometry. Conclusions This work represents the first demonstration that human platelets express EPCR and suggests that modulation of EPCR binding could be utilized to enhance the hemostatic efficacy of rationally designed FVIIa analogs.
Authors: Christine L Kempton; Maureane Hoffman; Harold R Roberts; Dougald M Monroe Journal: Arterioscler Thromb Vasc Biol Date: 2005-01-13 Impact factor: 8.311
Authors: Menno van Lummel; Maarten T T Pennings; Ronald H W M Derksen; Rolf T Urbanus; Bianca C H Lutters; Niels Kaldenhoven; Philip G de Groot Journal: J Biol Chem Date: 2005-08-09 Impact factor: 5.157
Authors: David Stacey; Lingyan Chen; Paulina J Stanczyk; Joanna M M Howson; Amy M Mason; Stephen Burgess; Stephen MacDonald; Jonathan Langdown; Harriett McKinney; Kate Downes; Neda Farahi; James E Peters; Saonli Basu; James S Pankow; Weihong Tang; Nathan Pankratz; Maria Sabater-Lleal; Paul S de Vries; Nicholas L Smith; Amy D Gelinas; Daniel J Schneider; Nebojsa Janjic; Nilesh J Samani; Shu Ye; Charlotte Summers; Edwin R Chilvers; John Danesh; Dirk S Paul Journal: Nat Commun Date: 2022-03-09 Impact factor: 17.694
Authors: Nikola Slaninova; Iveta Bryjova; Zenon Lasota; Radmila Richterova; Jan Kubicek; Martin Augustynek; Ayan Seal; Ondrej Krejcar; Antonino Proto Journal: Biomedicines Date: 2022-04-12